Literature DB >> 19886324

The natural history of chronic kidney disease revisited--a 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stage renal disease and death rates in 100 high-risk chronic kidney disease patients: a call for circumspection.

Macaulay A C Onuigbo1.   

Abstract

The natural history of chronic kidney disease (CKD), in general, remains conjectural. Current literature on rates of progression to end-stage renal disease (ESRD) as compared with mortality in CKD shows conflicts. A study of 27,998 patients in managed care reported a 5-year ESRD rate of 20% and a death rate of 50%. In 1666 patients in the Modification of Diet in Renal Disease study, a much higher ESRD rate of 60% after 88 months was reported (four times the death rate); among patients older than 65 years, the death rate approximated the ESRD rate. More than 20 million Americans have CKD [estimated glomerular filtration rate (eGFR) < 60 mL/min). Annually, approximately 100,000 new U.S. patients develop ESRD, accounting for a casual annual ESRD rate of only 0.5% among the U.S. CKD population. Similarly, this author's anecdotal experience suggests a more benign CKD outcome than is suggested by the two foregoing studies. A 72-month prospective report of an aging cohort of 100 CKD patients, high risk because they all experienced acute kidney injury at study entry, is presented. The finding of an approximately 18% ESRD rate and 13% death rate after 4 years contrasts sharply with the two studies cited earlier. Several factors--prospective as compared with retrospective analysis, varying patient age and other variables, managed care as compared with other care, and other unknown variables--play important roles in CKD outcome. This author agrees with researchers who recently emphasized the heterogeneity of the CKD population. Patient prognosis and management must be individualized.

Entities:  

Mesh:

Year:  2009        PMID: 19886324

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  5 in total

1.  Variability in CKD stage in outpatients followed in two large renal clinics: implications for CKD trials and the status of current knowledge of patterns of CKD to ESRD progression.

Authors:  Macaulay A Onuigbo; Nnonyelum T Onuigbo
Journal:  Int Urol Nephrol       Date:  2011-08-30       Impact factor: 2.370

Review 2.  Chronic kidney disease prediction is an inexact science: The concept of "progressors" and "nonprogressors".

Authors:  Macaulay Amechi Chukwukadibia Onuigbo; Nneoma Agbasi
Journal:  World J Nephrol       Date:  2014-08-06

Review 3.  Diabetic Nephropathy and CKD-Analysis of Individual Patient Serum Creatinine Trajectories: A Forgotten Diagnostic Methodology for Diabetic CKD Prognostication and Prediction.

Authors:  Macaulay Amechi Chukwukadibia Onuigbo; Nneoma Agbasi
Journal:  J Clin Med       Date:  2015-06-26       Impact factor: 4.241

4.  Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes.

Authors:  Chin-Lin Tseng; Jean-Philippe Lafrance; Shou-En Lu; Orysya Soroka; Donald R Miller; Miriam Maney; Leonard M Pogach
Journal:  BMC Nephrol       Date:  2015-03-25       Impact factor: 2.388

5.  Renoprotection and the Bardoxolone Methyl Story - Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents.

Authors:  Macaulay Onuigbo
Journal:  Nephron Extra       Date:  2013-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.